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Surgical delivery of drug releasing
poly(lactic-co-glycolic acid)/poly(ethylene glycol)
paste with in vivo effects against glioblastoma
SJ Smith, CV Rahman, PA Clarke, AA Ritchie, TW Gould, JH Ward, KM Shakesheff,
RG Grundy, R Rahman
University of Nottingham, UK
ABSTRACT
INTRODUCTION The median survival of patients with glioblastoma multiforme (astrocytoma grade 4) remains less than
18 months despite radical surgery, radiotherapy and systemic chemotherapy. Surgical implantation of chemotherapy eluting
wafers into the resection cavity has been shown to improve length of survival but the current licensed therapy has several draw-
backs. This paper investigates in vivo efficacy of a novel drug eluting paste in glioblastoma.
METHODS Poly(lactic-co-glycolic acid)/poly(ethylene glycol) (PLGA/PEG) self-sintering paste was loaded with the chemothera-
peutic agent etoposide and delivered surgically into partially resected tumours in a flank murine glioblastoma xenograft model.
RESULTS Surgical delivery of the paste was successful and practical, with no toxicity or surgical morbidity to the animals. The
paste was retained in the tumour cavity, and preliminary results suggest a useful antitumour and antiangiogenic effect, particu-
larly at higher doses. Bioluminescent imaging was not affected significantly by the presence of the paste in the tumour.
CONCLUSIONS Chemotherapy loaded PLGA/PEG paste seems to be a promising technology capable of delivering active drugs
into partially resected tumours. The preliminary results of this study suggest efficacy with no toxicity and will lead to larger
scale efficacy studies in orthotopic glioblastoma models.
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Glioblastoma multiforme (GBM) (astrocytoma grade 4) is an
aggressive, rapidly growing malignant brain tumour that
remains incurable. Current optimal therapy consists of neu-
rosurgical resection to as radical a degree as the tumour and
neuroanatomy allows, followed by radical radiotherapy
(60Gy) with adjuvant chemotherapy. Despite this multimo-
dal approach, median survival remains poor at 14 months or
less.1 It is clear that progress in management of high grade
brain tumours has lagged behind that of other cancers with
survival times only increasing minimally in recent years.
Complete surgical removal of these tumours is almost
never possible owing to their infiltrative nature. Even when
all tumour visible to the naked eye or on conventional pre-
operative magnetic resonance imaging is resected, remnant
tumour cells remain in what appears macroscopically or
radiologically to be normal brain.2 These infiltrative cells
are resistant to radiotherapy, the dose of which is limited by
neurotoxicity to normal brain.
Improvements in survival have been achieved with the
chemotherapeutic agent temozolomide, which has been
shown to be especially beneficial in individuals with
a methylated promoter sequence for the methylguanine
methyltransferase gene.3 Other forms of systemic chemo-
therapy, including molecularly targeted therapy, have not
been shown to have significant survival benefits in humans,
partly because of the difficulties of delivering adequate con-
centrations of agents across the blood–brain barrier (BBB) to
achieve a dose lethal to tumour cells in the brain. Indeed, no
therapy based on the molecular biology of GBM has yet
shown efficacy in a phase III trial.4
One surgical approach that has demonstrated positive
impact on survival has been the use of carmustine impreg-
nated wafers (Gliadel®; Arbor Pharmaceuticals, Atlanta, GA,
US) to deliver intracavity chemotherapy.5 Implanted by the
operating neurosurgeon after maximal tumour resection
has occurred (at least 90% to comply with National Institute
for Health and Care Excellence [NICE] guidelines for prod-
uct usage in the National Health Service [NHS]),6,7 these bio-
degradable polymer wafers release the chemotherapeutic
alkylating agent carmustine, which spreads by diffusion into
the surrounding brain parenchyma and has antineoplastic
effects against the remnant infiltrating tumour cells that
cannot be removed surgically without causing catastrophic
morbidity.
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Gliadel® has been shown in a randomised multicentre
phase III trial to have a small but statistically significant
survival benefit in GBM of 2–3 months.7 Despite this evi-
dence, and its subsequent licensing and approval for NHS
funding, uptake has been limited by concerns regarding
possible increases in operative complication rates, particu-
larly wound healing and infection. Some surgical series
have reported a significant increase in wound infections
following craniotomy,8,9 leading to increased hospital stays
for patients who already have limited life expectancy.
The drug release kinetics for Gliadel® show a high burst
of release occurring in the first few days after implantation,
with this surge of cytotoxic agent potentially responsible
for the impaired wound healing observed.10 Conformity of
the rigid wafer to the irregular resection cavity wall can
also be poor as wafers can displace with gravity. In addi-
tion, Gliadel® uses a monotherapeutic approach that may
swiftly be countered by the rise of resistant tumour clones
in the GBM.
A novel temperature sensitive and biodegradable drug
carrying paste based on poly(lactic-co-glycolic acid)/poly
(ethylene glycol) (PLGA/PEG) has been developed in
Nottingham.11,12 PLGA is non-toxic with US Food and
Drug Administration approval for certain clinical applica-
tions such as in resorbable sutures. The PLGA/PEG par-
ticles in the Nottingham formulation form a malleable
paste at room temperature when mixed with water or sal-
ine. The particles then fuse together at body temperature,
causing the paste to solidify gently, with no exothermic
reaction.13 In vitro studies have demonstrated release of
active chemotherapeutic agents from the formulation over
three weeks at body temperature.14 The controlled release
of multiple drugs concurrently is possible (Gould TW et al,
unpublished data).
The effect of therapy on blood vessel development in a
tumour is a key component of an anticancer drug. Reduc-
tion in blood vessel growth in the tumour will reduce the
supply of nutrients to a tumour, slowing growth kinetics by
depriving the tumour of vital substrates including oxy-
gen.15 Evidence is also accumulating that antiangiogenic
therapy may depend on the destruction of the perivascular
tissue niche that is particularly favourable for the growth
of GBM cells,16 particularly stem-like cells, which may con-
fer resistance to oncological therapy.17
This study examined the effects of etoposide loaded
PLGA/PEG paste in a murine flank/human GBM xenograft.
The surgical relevance of this model was enhanced by
undertaking partial resection of the tumour to mimic the
clinical situation where even radical surgery leaves rem-
nant tumour behind, concealed in apparently normal brain.
The characteristics were studied of the paste in situ in the
animal and its effects on the imaging techniques used to
monitor tumour growth. The effects of drug release on the
surrounding tumour were also investigated with particular
focus on markers of blood vessels and angiogenesis. Fur-
thermore, this study presents preliminary data suggesting
a useful effect in controlling tumour growth although stat-
istical examination of survival benefit will be required in
future larger therapy experiments.
Methods
Particle production was as described previously14 at a
ratio of 93.5%:6.5% PLGA:PEG. Particles were sieved to
achieve a consistent sizing of 100–200mm. They were
mixed with the etoposide drug solution at a ratio of 1:0.6
particles:solution (weight/volume). Drug concentration was
at either 80mg/kg, 160mg/kg or 320mg/kg as per the ani-
mals’ body weight. Etoposide was purchased from Sigma
(Gillingham, Dorset, UK) and resuspended in dimethyl
sulfoxide.
This study was approved by the University of Notting-
ham local ethical review committee and the UK Home
Office (licence number PPL 40/3559) after consideration of
the justification of animal research and good animal wel-
fare. Fifteen 4–6-week-old male MF1 nude mice (three
mice with equivalent sized tumours per arm) were main-
tained under standard conditions as detailed in the Animals
(Scientific Procedures) Act 1986, and studies were con-
ducted and reported in compliance with the 2010 NC3Rs
ARRIVE (Animal Research: Reporting of In Vivo Experi-
ments) guidelines.18
U87 or U373 human GBM cells tagged with a biolumi-
nescent marker were injected subcutaneously into the ani-
mals’ left flank and the tumour was grown for 15 days
while monitored using the IVIS® Spectrum bioluminescent
imaging system (PerkinElmer, Cambridge, UK). Mice with
satisfactory tumour take and growth rates underwent par-
tial tumour resection. The previous flank incision was
reopened and a biopsy punch and fine suction tip used to
resect the tumour back to near the tumour–tissue interface,
resecting approximately 75% of visible tumour, thereby
mimicking the surgical technique used in human patients
undergoing comparable surgery for GBM.
Etoposide loaded PLGA/PEG matrices (80mg/kg, 160mg/
kg or 320mg/kg) (experimental arms) or blank PLGA/PEG
matrices (control arm) were moulded into the resection
cavity. Mice were monitored by two and three-dimensional
bioluminescent imaging of established tumours prior to
implantation and weekly until termination to assess tumour
growth. The tumour was positioned uppermost to gain max-
imum imaging sensitivity. Animals were weighed daily by
an experienced technician, any adverse effects noted and
sacrificed using cervical dislocation to ameliorate suffering
once their clinical condition deteriorated. Mice were sacri-
ficed at a maximum of 28 days following implantation of
PLGA/PEG.
Anti-Ki-67 (monoclonal mouse antihuman Ki-67 antigen,
clone MIB-1; Dako, Ely, UK) and anti-VEGF (monoclonal
mouse antihuman vascular endothelial growth factor, clone
VG1; Dako) were used at 1:50 concentration, and anti-
endoglin (ab49679; Abcam, Cambridge, UK) was applied at
1:100. All primary antibodies were applied for one hour at
room temperature. A secondary antibody (100ml horserad-
ish peroxidase conjugated rabbit antimouse; Dako) was
applied for 30 minutes at room temperature. 2ml of 3,3'-
diaminobenzidine chromogen in 98ml of REAL™ substrate
buffer (Dako) was applied before haematoxylin counter-
staining and mounting.
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Results
PLGA/PEG does not interfere significantly with
bioluminescent imaging
In order to examine the difference between paste and tissue,
a tumour was excised from a mouse rejected from the main
study owing to a low bioluminescence of less than 2 ! 106
photons per second total flux as measured through the intact
skin. This large tumour was dissected immediately after
imaging while still bioluminescent and was imaged to obtain
a base level photon reading. It was then coated with a blank
PLGA/PEG matrix to assess the level of light blockade (Figs
1A and 1B). When the tumour was excised, the unimpeded
flux measurement ex vivo rose to 9 ! 107 photons per second.
Coating with PLGA/PEG reduced flux to 3.6 ! 107 photons
per second (Fig 1C). The PLGA/PEG coating therefore causes
a low level of signal blockade (a 2.7:1 reduction). Skin alone
impedes light signal by a 5:1 reduction. The effect of surgical
resection was easily visible using bioluminescent imaging,
with the cavity clearly visualised, allowing standardisation for
the amount of resection undertaken (Fig 1D).
PLGA/PEG effects remain localised in vivo
The tumour implanted with PLGA/PEG was excised 28
days following implantation, and examined macroscopi-
cally and microscopically. The paste remained entirely in
the resection cavity with no spillage into the surrounding
flank tissues of the animal (Fig 2A). There was good
adherence to the cavity wall with coverage of the entire
cavity, providing intimate contact between the maximum
extent of the tumour and the drug delivery source. The
histology findings on Figure 2B illustrate PLGA/PEG form-
ing a close approximation to the tumour (even allowing for
a degree of tissue retraction following fixation). In an ex
vivo ovine brain, the paste remained attached even when
spread thinly as a 2mm thick lining to a brain resection
cavity (Fig 2C). The PLGA/PEG retained its characteristic
microparticulate structure after implantation (Fig 2D) with
particles of approximately 100mm.
Animal weights for all groups, including the higher doses
of etoposide delivery, continued to increase throughout the
study period, indicating preservation of the animals’ general
health. Systemic delivery of etoposide is associated with
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Figure 1 Effects of poly(lactic-co-glycolic acid)/poly(ethylene glycol) (PLGA/PEG) on bioluminescent monitoring of tumours
Top: Xenograft of U87 human glioblastoma cell line grown in murine flank, excised, with bioluminescence measured before (A) and after
(B) application of layer of PLGA/PEG, demonstrating reduction with coating of the biomaterial
Bottom: Comparison of flux levels between coated and non-coated tumours demonstrating some reduction but to a lesser degree than with
normal tissues (C), and bioluminescent imaging of mouse demonstrating tumour with resected core (arrow) (D)
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typical cytotoxic adverse events but in these experiments, no
such events were observed, suggesting no significant sys-
temic effect from the localised delivery of the chemotherapy
(Fig 3).
Localised drug release has antiangiogenic effects
Histological examination of tumours resected after 28 days
demonstrated tumour necrosis in the immediate vicinity, as
reported previously.14 The tumour tissue was also stained
using the Ki-67 (MIB-1) marker for cell proliferation and
markedly decreased levels of proliferating cells were found
after exposure to the locally released etoposide compared
with animals implanted with blank PLGA/PEG paste (Fig 4).
Similarly, levels of vascular endothelial growth factor stain-
ing were reduced significantly following 28 days of exposure
to the etoposide loaded PLGA/PEG but not with blank PLGA/
PEG. Immunohistochemistry was also performed to exam-
ine the number of vessels staining positive for the neoangio-
genic marker endoglin. In a similar fashion, levels of new
vessels in the adjacent tumour were reduced after usage of
etoposide loaded but not blank PLGA/PEG (Fig 4).
A B
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Figure 2 Poly(lactic-co-glycolic acid)/poly(ethylene glycol)
(PLGA/PEG) application in vivo
A: Excised U373 human glioblastoma murine flank xenograft 28
days following implantation, dissected in half, demonstrating
central pale core of PLGA/PEG retained in surrounding tumour
B: Histology of tumour on left demonstrating PLGA/PEG matrix
(*) closely opposed to tumour (#)
C: Ex vivo ovine model with cavity resection in brain, lined with
pale PLGA/PEG sintered into place, and retaining shape and
apposition to cavity walls
D: Scanning electron micrography of PLGA/PEG matrix
microparticles
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Figure 3 Animal weights after surgical implantation of blank
poly(lactic-co-glycolic acid)/poly(ethylene glycol) (PLGA/PEG),
PLGA/PEG with 80mg/kg etoposide and PLGA/PEG with
160mg/kg etoposide
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Figure 4 Immunohistochemistry in murine flank xenografts
A&D: Staining for Ki-67 proliferation marker in a U87 murine
flank xenograft partially resected and treated with blank poly
(lactic-co-glycolic acid)/poly(ethylene glycol) (PLGA/PEG) (A) or
PLGA/PEG loaded with 160mg/kg etoposide (D), showing reduc-
tion in tumour cell proliferation in response to active etoposide
release
B&E: Staining for vascular endothelial growth factor (VEGF) in
a U87 murine flank xenograft partially resected and treated
with blank PLGA/PEG (B) or PLGA/PEG loaded with 160mg/kg
etoposide (E), showing reduction in VEGF positivity
C&F: Staining for the angiogenic vessel marker endoglin, show-
ing new vessel formation in a U87 murine flank xenograft
treated with blank PLGA/PEG (C) but not for PLGA/PEG loaded
with 160mg/kg etoposide (F)
G: Low power view of an excised U87 murine flank xenograft
treated with PLGA/PEG loaded with 160mg/kg etoposide
showing the inner zone of necrosis, more viable tumour
centrally and the outer capsule of normal mouse tissue
H: Immunostaining for endoglin in a U87 murine flank xeno-
graft treated with PLGA/PEG loaded with 160mg/kg etoposide
showing damaged blood vessels in highly necrotic tissue
I: Immunostaining for VEGF with tumour cells growing around
blank PLGA/PEG particles showing the non-toxic nature of the
carrier biomaterial
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Intracavity etoposide release slows tumour growth
Serial examination of the bioluminescence levels in
tumours demonstrated substantial reduction in growth in
tumours treated with the higher dose (160mg/kg) of etopo-
side, which persisted until 21 days following implantation
(Fig 5). After this time, tumour regrowth began to occur at
the 28-day timepoint, consistent with our in vitro data,
which suggests drug release ceases at the 21-day time-
point. Tumour regrowth at this stage was rapid as the
tumour ‘rebounded’ and the remnant tumour cells could
now grow unopposed. In the clinical situation, patients
would normally commence radiotherapy and temozolo-
mide three weeks after surgery, which should prevent a
similar phenomenon. At the highest etoposide dosage level,
substantial reduction in tumour bioluminescence occurred,
a correlate of reduced tumour activity and burden.
Discussion
GBM remains an essentially incurable malignant brain
tumour for which surgery can reduce disease volume and
prolong survival. However, disease recurrence is almost
inevitable as infiltrative malignant cell populations remain
in the surrounding brain parenchyma. Adjuvant oncological
treatment with radiotherapy and temozolomide improves
survival but still cannot eradicate the invasive cancer cells.
The choice and efficacy of chemotherapy agents is limited
by their ability to cross the BBB. Escalating systemic doses of
drug to achieve effective levels in the brain itself results in
unacceptable toxicity (eg bone marrow suppression).
One approach to achieve high concentrations of chemo-
therapy in the brain but low toxic doses systemically is to
surgically implant chemotherapy depot material to release
the drug over a period of time. This directly bypasses the
BBB, enhancing the local dose while minimising exposure
of other organs such as the bone marrow and liver. The only
NICE approved application of this technique is Gliadel®
(carmustine) wafers.7 Although they do prolong survival by
a short but significant amount, their efficacy is limited by
technical factors. They have poor resection cavity conform-
ity, delivery is limited to one agent and drug release is rapid
with all drug eluted off the wafers by one week.10 Most
patients in the UK wait three weeks between surgery and
commencement of adjuvant therapy. Surgically implanted
PLGA/PEG with its gradual drug release over 3–4 weeks has
the potential to fill this ‘therapy gap’ as a possibly more
effective delivery system for intracavity chemotherapy.
It has been demonstrated previously that PLGA/PEG has
physical characteristics that make it extremely attractive sur-
gically.14 It is applied as a malleable paste at room tempera-
ture, allowing close tissue approximation to the infiltrated
brain parenchyma, and sinters gently (in a non-exothermic
fashion) at body temperature, causing retention at the site of
application. It can deliver a combination of chemotherapeutic
agents over a prolonged time course, and the released agents
retain cytotoxicity in vitro and in vivo. It is not affected by
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Figure 5 In vivo effects of drug eluting poly(lactic-co-glycolic acid)/poly(ethylene glycol) (PLGA/PEG)
A: Tumour growth following partial tumour resection and implantation of blank PLGA/PEG, PLGA/PEG with 80mg/kg etoposide and PLGA/
PEG with 160mg/kg etoposide. The higher dose PLGA/PEG with etoposide demonstrated reduction in tumour growth in the animals until
day 21, when in vitro studies predicted drug release would stop. By the day 28 measurement, tumour growth had resumed at a rapid
rate.
B: Sample bioluminescent image of two mice with partial resection of a U373 flank xenograft, mouse on left with blank PLGA/PEG and
mouse on right with PLGA/PEG loaded with 320mg/kg etoposide, showing considerable reduction in bioluminescence and corresponding
reduction in tumour load
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clinically relevant doses of radiation, it is non-toxic, and iden-
tifiable on computed tomography and magnetic resonance
imaging in relation to the brain.
In the current study, we demonstrate that PLGA/PEG
does not interfere with the bioluminescent imaging system
used to assess tumour growth. There is a possibility that
the paste could interfere marginally with a weaker signal if
it is positioned directly between the camera and the signal
source but at a much lower level than that observed in
pre-existing tissue such as skin, muscle and bone. If used
as a packing agent in a debulked tumour, the paste is likely
to reduce light signal from the tissue compartment below
it at a low level and have minimal effect on the rest of the
remaining tumour other than alteration of the direction of
light refraction. PLGA/PEG retains its position in the
tumour in a living animal and does not spread outside of
the target region.
Tumour necrosis has been demonstrated previously in
response to the release of the cytotoxic agent etoposide
from PLGA/PEG paste in vivo.14 The present study extended
these findings to show reduction in other critical markers of
tumour growth such as cell proliferation, release of proan-
giogenic factors and the development of new blood vessels.
This suggests that the released drug is having meaningful
antineoplastic effects, and interfering with tumour growth
beyond the zone of obvious cell death and necrosis.
Disruption of the development of new microvascula-
ture19 has been associated with disruption of the suppor-
tive tumour microenvironment (the perivascular niche)
that allows GBM to grow and invade so rapidly.20 In partic-
ular, this disruption of the blood vessel network may deny
tumour stem-like cells a supportive refuge in which they
can resist the effects of adjuvant oncological therapy.21–23
The current ‘therapy gap’ can therefore be used as a time
for surgically implanted therapy to target the residual inva-
sive cell population and potentially act as a sensitiser for
radio or chemotherapies.
Even with this limited examination of a relatively low
dose of single agent etoposide, antitumour effects can be
demonstrated in the animals. With the caveat of low sam-
ple numbers, there appears to be a drug response in the
high dose etoposide loaded PLGA/PEG group compared
with the control PLGA/PEG group and the 80mg/kg etopo-
side loaded PLGA/PEG group over 21 days following
implantation. By day 28, the tumours in this responsive
group appear to be escaping drug control, as may be
expected from the in vitro drug release kinetics, whereby
drug release tailed off at the 21-day mark.14 No substantial
side effects were demonstrated in any group due to sys-
temic toxicity.
Efforts will now focus on higher doses of etoposide and
combining this with multiple agents such as temozolomide
or a poly(ADP-ribose) polymerase inhibitor. PLGA/PEG has
the potential to deliver a wide variety or combinations of
agents and may even be suitable for delivering viruses or
genetic material. This trial was terminated at 28 days fol-
lowing surgery, and future studies will focus on animal
survival and be powered to examine this statistically.
Clearly, the current animal model is limited by implanta-
tion of the tumour in the animal flank rather than in the
brain. We are currently engaged in developing an ortho-
topic partial resection brain tumour model, which will
allow toxicity and efficacy testing in a setting equivalent to
the intended clinical usage in humans. Although no toxicity
was seen in the current model, we would anticipate that
systemic exposure to the drug would be reduced by its
direct placement in the central nervous system and beyond
the BBB. This may allow higher doses of the drug to be
used although direct neurotoxicity will have to be moni-
tored. Tumour response is also dependent on the sur-
rounding microenvironment and this will have to be
evaluated carefully in an orthotopic setting as a prelude to
any future clinical human trial.
Conclusions
Surgical intracavity drug delivery using the PLGA/PEG sys-
tem is a safe and effective way of releasing chemothera-
peutic agents (in this case, etoposide) in a living animal. It
has the potential to be a useful adjunct to current therapy
for GBM, seemingly extending survival for this highly
aggressive tumour.
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